US HB4187 | 2013-2014 | 113th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on March 11 2014 - 25% progression, died in committee
Action: 2014-03-14 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on March 11 2014 - 25% progression, died in committee
Action: 2014-03-14 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 or DISARM Act of 2014 - Amends title XVIII (Medicare) of the Social Security Act to direct the Secretary of Health and Human Services (HHS) to: (1) recognize the costs of new antimicrobial drugs under the Medicare payment system for the inpatient services of subsection (d) hospitals, (2) provide for additional payment with respect to discharges involving such drugs, (3) publish in the Federal Register a list of the new antimicrobial drugs, and (4) further reduce each of the average standardized payment amounts in a specified manner to maintain budget neutrality in a fiscal year beginning with FY2015. (Generally, a subsection [d] hospital is an acute care hospital, particularly one that receives payments under Medicare's inpatient prospective payment system [IPPS] when providing covered inpatient services to eligible beneficiaries.) Directs the Comptroller General (GAO) to study the barriers that prevent the development of new antimicrobial drugs and develop recommendations for actions to be taken in order to overcome such barriers.
Title
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
Sponsors
Rep. Peter Roskam [R-IL] | Rep. Charles Boustany [R-LA] | Rep. Robert Brady [D-PA] | Rep. Vern Buchanan [R-FL] |
Rep. Larry Bucshon [R-IN] | Rep. Danny Davis [D-IL] | Rep. Renee Ellmers [R-NC] | Rep. Jim Gerlach [R-PA] |
Rep. Phil Gingrey [R-GA] | Rep. Gene Green [D-TX] | Rep. Lynn Jenkins [R-KS] | Rep. Mike Kelly [R-PA] |
Rep. John Larson [D-CT] | Sen. Ben Lujan [D-NM] | Rep. Patrick Meehan [R-PA] | Rep. Devin Nunes [R-CA] |
Rep. Bill Pascrell [D-NJ] | Rep. Donald Payne [D-NJ] | Rep. Linda Sanchez [D-CA] | Rep. Albio Sires [D-NJ] |
History
Date | Chamber | Action |
---|---|---|
2014-03-14 | House | Referred to the Subcommittee on Health. |
2014-03-11 | House | Referred to House Energy and Commerce |
2014-03-11 | House | Referred to House Ways and Means |
2014-03-11 | House | Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Subjects
Congressional oversight
Drug safety, medical device, and laboratory regulation
Government studies and investigations
Health
Infectious and parasitic diseases
Medicare
Prescription drugs
Product development and innovation
Drug safety, medical device, and laboratory regulation
Government studies and investigations
Health
Infectious and parasitic diseases
Medicare
Prescription drugs
Product development and innovation
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/113th-congress/house-bill/4187/all-info |
Text | https://www.congress.gov/113/bills/hr4187/BILLS-113hr4187ih.pdf |